Treatment of Urinary Tract Infections (Uncomplicated vs. Complicated)

Definitions

Uncomplicated UTI refers to cystitis or pyelonephritis in otherwise healthy, non-pregnant, pre-menopausal women with no anatomic or functional urinary tract abnormalities. The most common pathogens are E. coli (80-85%), Staphylococcus saprophyticus, and Klebsiella spp.

Complicated UTI is infection associated with any factor that increases risk of treatment failure or serious outcomes, including:

Male sex
Pregnancy
Diabetes mellitus
Structural/functional urinary tract abnormality (obstruction, calculi, reflux)
Indwelling urinary catheter
Renal impairment
Immunocompromised state
Hospital-acquired (nosocomial) infection

Bacteriuria thresholds differ: uncomplicated cystitis requires only ≥10² CFU/mL of E. coli or S. saprophyticus; complicated UTI typically requires ≥10³ CFU/mL (though lower counts in symptomatic patients are still clinically significant).

1. Uncomplicated UTI (Acute Cystitis in Women)

First-line Agents (IDSA/ESCMID Guidelines)

Agent	Dose & Duration	Notes
Nitrofurantoin (monohydrate/macrocrystals)	100 mg BID × 5 days	Fewest adverse effects; avoid if eGFR <30 mL/min; not suitable for pyelonephritis
TMP-SMX DS (160/800 mg)	1 tab BID × 3 days	Only if local resistance <20%; highly effective for susceptible organisms
Fosfomycin	3 g single dose	Resistance rate ~2%; suitable for ESBL-producing E. coli; slightly lower efficacy than other regimens
Pivmecillinam	400 mg BID × 5 days	Available in Europe; avoid if early pyelonephritis suspected

Second-line Agents (when above cannot be used)

Cefpodoxime, cefdinir, or cefaclor: 3-7 day regimens
Amoxicillin-clavulanate: less effective against enterobacteria, promotes Klebsiella selection - not preferred
Fluoroquinolones (ciprofloxacin, levofloxacin): effective but should be reserved for more serious infections due to resistance stewardship concerns

Key points:

No urine culture required for classic presentation of uncomplicated cystitis in otherwise healthy women
Symptomatic women who do not receive antimicrobials will typically resolve within 1-2 weeks, but treatment speeds resolution and prevents progression
Aminopenicillins (amoxicillin, ampicillin) are not recommended as first-line due to poor efficacy

2. Uncomplicated Pyelonephritis (Outpatient-Eligible)

For mild-moderate pyelonephritis without systemic compromise, oral therapy is appropriate:

Agent	Dose & Duration
Ciprofloxacin	500 mg BID × 7 days
Levofloxacin	750 mg once daily × 5 days
TMP-SMX DS	BID × 14 days (only if susceptibility confirmed)
Oral beta-lactam	10-14 days (e.g., cefpodoxime) - less efficacy than fluoroquinolones

Fluoroquinolones are the preferred outpatient choice for pyelonephritis
A single dose of a long-acting parenteral antibiotic (ceftriaxone 1g IV/IM or an aminoglycoside) is sometimes added upfront if resistance is a concern
Nitrofurantoin is not appropriate for pyelonephritis (inadequate renal tissue levels)

3. Complicated UTI and Inpatient Pyelonephritis

Urine culture (and blood cultures if systemically unwell) is mandatory before starting antibiotics.

Empiric Inpatient Regimens

Severity	Preferred Agents
Moderate (hospitalized, no sepsis)	Ceftriaxone 1g IV daily; Ciprofloxacin 400 mg IV Q12h; Levofloxacin 750 mg IV daily
Severe / Sepsis	Piperacillin-tazobactam 3.375g IV Q6h or 4.5g IV Q6h; Cefepime 1-2g IV Q8-12h
Suspected ESBL or history of resistant organisms	Ertapenem 1g IV daily; Meropenem or imipenem for critically ill
Pseudomonas risk (ICU, structural lung/urinary disease)	Piperacillin-tazobactam; Cefepime; or Meropenem

Duration

Complicated cystitis: 7-14 days depending on pathogen and host
Complicated pyelonephritis: 14 days (consider 21 days if slow response)
Catheter-associated UTI (CA-UTI): 7 days if prompt clinical response; remove/replace catheter when possible

Special populations

Pregnant women:

Asymptomatic bacteriuria must be treated (risk of pyelonephritis and preterm labor)
Safe agents: nitrofurantoin (avoid near term), cephalexin, amoxicillin-clavulanate, fosfomycin
Avoid: fluoroquinolones, TMP-SMX (especially 1st trimester - folate antagonism; 3rd trimester - neonatal jaundice), tetracyclines

Males:

Always obtain urine culture
Most male cystitis is treated as complicated; longer courses (7-14 days) are generally used
Rule out prostatitis (requires 4-6 weeks of a fluoroquinolone if present)

Diabetic patients:

Risk of emphysematous pyelonephritis and fungal infections; requires imaging if not improving in 48-72 hours

Catheter-associated UTI:

Remove/change catheter; obtain culture from new catheter or midstream specimen
7 days treatment; longer if delayed response

4. Fungal UTI (Candiduria)

Treat only when symptomatic:

Fluconazole 400 mg loading dose, then 200 mg daily × 7-14 days
If Candida spp resistant to fluconazole: liposomal amphotericin B (other antifungals have limited renal excretion)

5. Recurrent UTI - Prophylaxis

For women with ≥2 episodes in 6 months or ≥3 in 12 months:

Strategy	Agents
Long-term low-dose prophylaxis	Nitrofurantoin 50-100 mg daily; TMP-SMX 40/200 mg daily or alternate days; Cephalexin 250-500 mg daily
Postcoital prophylaxis	Nitrofurantoin 50-100 mg; TMP-SMX 40/200 mg; Trimethoprim 100 mg single dose after intercourse
Patient-initiated self-treatment	Short course with nitrofurantoin or TMP-SMX at symptom onset
Non-antibiotic options	D-mannose 420 mg to 2g (especially for E. coli); increased fluid intake >1.5 L/day; avoid spermicides; vaginal estrogen (postmenopausal women)

6. When to Image

Imaging is generally not required for uncomplicated UTI managed as an outpatient. Indications include:

Failure to respond to antibiotics within 48-72 hours
Suspected obstruction, renal abscess, or nephrolithiasis
Emphysematous pyelonephritis (CT is the modality of choice - US and plain film have poor sensitivity)
Male patients, elderly, diabetic, or severely ill patients
Postvoid residual >180 mL in men (predisposes to bacteriuria)

Summary - Quick Drug Selection Table

Scenario	Preferred Agent	Duration
Uncomplicated cystitis (women)	Nitrofurantoin 100 mg BID	5 days
Uncomplicated cystitis (alternative)	TMP-SMX DS	3 days
Single-dose option	Fosfomycin 3g	1 dose
Outpatient pyelonephritis	Ciprofloxacin 500 mg BID	7 days
Inpatient pyelonephritis	Ceftriaxone 1g IV daily	7-14 days
Complicated UTI / sepsis	Piperacillin-tazobactam or Cefepime IV	7-14 days
ESBL-suspected	Ertapenem 1g IV	14 days
Fungal (symptomatic)	Fluconazole 200 mg	7-14 days
Recurrent UTI prophylaxis	Nitrofurantoin 50-100 mg daily	Long-term

Sources:

Tintinalli's Emergency Medicine, Table 91-5 and 91-6
Goldman-Cecil Medicine, Chapter 263 (Treatment of UTI)
Comprehensive Clinical Nephrology 7th Ed., Chapter 53
Nelson Z et al. (2024). WikiGuidelines UTI Consensus Statement. JAMA Network Open (PMID: 39495518)

Recent evidence note: A 2024 WikiGuidelines consensus statement (PMID: 39495518) across adult and pediatric populations reinforces nitrofurantoin and fosfomycin as preferred first-line agents for uncomplicated cystitis and emphasizes antibiotic stewardship by reserving fluoroquinolones for complicated/upper tract infections.

This is a shared conversation. Sign in to Orris to start your own chat.